Despite the benefit of endocrine therapy, acquired resistance during or after treatment still remains a major challenge in estrogen receptor (ER)–positive breast cancer. We investigated the potential role of histone demethylase retinoblastoma-binding protein 2 (RBP2) in endocrine therapy resistance of breast cancer.

中文翻译：

---

RBP2诱导的ER和IGF1R-ErbB信号在乳腺癌中对他莫昔芬耐药的作用

尽管有内分泌治疗的益处，但治疗期间或治疗后获得的耐药性仍然是雌激素受体（ER）阳性乳腺癌的主要挑战。我们调查了组蛋白脱甲基酶视网膜母细胞瘤结合蛋白2（RBP2）在乳腺癌的内分泌治疗耐药性中的潜在作用。